46 mISK to develop proof of concept
RANNÍS has awarded Akthelia a grant from their Vöxtur program. Total grant is 46 mISK over two years. This grant increases greatly the scope of Akthelia’s development program. Akthelia’s main current goal is to show proof of concept in an established animal infection model.
Akthelia has developed and patented a class of small molecules that modulate the body’s innate immunity, leading to elimination of bacteria and clearing of infections. Instead of administering antibiotics, Akthelia’s approach acts like a switch that turns on our innate antimicrobial defences and strengthens epithelial cell walls and has been shown to work against multiple pathogens, including resistant ones. The compounds might constitute the first broad spectrum antibiotic that does not negatively impact the body’s internal bacterial flora.